Edesa Biotech (EDSA) CEO adds 1,000 shares in open-market buy

Rhea-AI Filing Summary

Edesa Biotech, Inc. Chief Executive Officer Pardeep Nijhawan reported an open-market purchase of 1,000 Common Shares on March 10, 2026 at an average price of $6.5989 per share. Following this transaction, his direct holdings increased to 628,813 Common Shares.

He also reports indirect ownership positions, including 402,702 Common Shares held by Pardeep Nijhawan Medicine Professional Corporation and additional blocks held by The New Nijhawan Family Trust 2015, The Digestive Health Clinic Inc., and 1968160 Ontario Inc. He disclaims beneficial ownership of these indirect holdings except to the extent of his pecuniary interest.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Nijhawan Pardeep

(Last) (First) (Middle)

C/O EDESA BIOTECH INC.

100 SPY COURT

(Street)

MARKHAM A6 L3R 5H6

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Edesa Biotech, Inc. [ EDSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	03/10/2026		P		1,000	A	$6.5989	628,813	D
Common Shares								402,702	I	Held by Pardeep Nijhawan Medicine Professional Corporation(1)
Common Shares								32,609	I	Held by The New Nijhawan Family Trust 2015(1)
Common Shares								32,013	I	Held by The Digestive Health Clinic Inc.(2)
Common Shares								53,104	I	Held by 1968160 Ontario Inc.(1)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Each of Pardeep Medicine Professional Corporation, The Digestive Health Clinic Inc. and 1968160 Ontario Inc. are wholly-owned by Reporting Person. Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

2. Reporting Person is a co-trustee of The New Nijhawan Family Trust 2015. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

	/s/ Peter J. Weiler, Attorney-in-Fact for Pardeep Nijhawan	03/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Edesa Biotech (EDSA) report for its CEO?

Edesa Biotech CEO Pardeep Nijhawan reported buying 1,000 Common Shares in the open market. The purchase occurred on March 10, 2026, at an average price of $6.5989 per share, modestly increasing his directly held stake in the company.

How many Edesa Biotech (EDSA) shares does the CEO hold after this Form 4?

After the reported trade, CEO Pardeep Nijhawan directly holds 628,813 Common Shares of Edesa Biotech. The Form 4 also lists several indirect holdings through entities and a family trust, where he formally disclaims beneficial ownership beyond his economic interest.

Was the Edesa Biotech (EDSA) CEO trade an open-market purchase or another type?

The filing identifies the CEO’s transaction as an open-market purchase of Common Shares. The transaction uses code “P,” which in Form 4 terminology indicates a purchase in the open market or a private transaction at the stated average price.

What indirect Edesa Biotech (EDSA) holdings are associated with the CEO?

The Form 4 shows indirect holdings through Pardeep Nijhawan Medicine Professional Corporation, The New Nijhawan Family Trust 2015, The Digestive Health Clinic Inc., and 1968160 Ontario Inc. Nijhawan disclaims beneficial ownership of these shares except for his pecuniary interest in those entities.

Does the Edesa Biotech (EDSA) CEO fully own the indirectly held shares listed?

The CEO does not claim full beneficial ownership of the indirect positions. The filing states he disclaims beneficial ownership of those securities, except to the extent of his pecuniary interest, and that their inclusion should not be considered an admission of full ownership.